Clinical Trials for Brain Tumor

A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults aged 2–21 years with recurrent or progressive B7-H3–expressing CNS embryonal tumors or ependymoma after standard therapy receive fludarabine/cyclophosphamide lymphodepletion followed by autologous B7-H3–targeted CAR T cells. The CAR T cells are given intravenously, with subsequent intracerebroventricular doses guided by response.

ClinicalTrials.gov ID: NCT07390539

A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, unresectable advanced or metastatic cancers harboring eligible KRAS non-G12C, BRAF, CRAF, or NRAS alterations receive oral BDTX-4933, an investigational RAF inhibitor designed to block signaling through active RAF dimers. Dose expansion is limited to patients with radiographically progressing KRAS non-G12C–mutant NSCLC.

ClinicalTrials.gov ID: NCT05786924

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, recurrent primary CNS tumors who have received standard treatment and have no remaining standard options receive single-agent oral ONC206 on intermittent weekly schedules. ONC206 is an investigational imipridone that activates mitochondrial ClpP and antagonizes the dopamine D2 receptor.

ClinicalTrials.gov ID: NCT04541082

A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 12 months to 21 years with relapsed or refractory solid tumors, CNS tumors, or lymphoma and no satisfactory curative option receive intravenous CBL0137, an investigational curaxin that disrupts DNA packaging and functionally inhibits the FACT chromatin complex. A disease-specific cohort enrolls patients with progressive or recurrent DIPG or other H3 K27-altered diffuse midline glioma after radiotherapy.

ClinicalTrials.gov ID: NCT04870944

A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults and children with relapsed or refractory high-risk neuroblastoma or osteosarcoma receive cyclophosphamide/fludarabine lymphodepletion followed by autologous GD2-targeted CAR T cells. The cells express IL-15 to enhance expansion and persistence and include an inducible caspase-9 safety switch.

ClinicalTrials.gov ID: NCT03721068

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with recurrent glioblastoma, newly diagnosed MGMT-unmethylated glioblastoma, or brain metastases from solid tumors receive escalating doses of AZD1390 with disease-specific radiotherapy; the brain-metastasis arm is closed to recruitment. AZD1390 is a brain-penetrant ATM kinase inhibitor intended to impair repair of radiation-induced DNA damage.

ClinicalTrials.gov ID: NCT03423628